#BEGIN_DRUGCARD DB01170

# AHFS_Codes:
24:08.32

# ATC_Codes:
C02CC02
S01EX01

# Absorption:
3-30% of oral dose (poor and highly variable)

# Biotransformation:
Guanethidine is converted by the liver to three metabolites, which are excreted in the urine. The metabolites are pharmacologically less active than the parent compound.

# Brand_Mixtures:
Not Available

# Brand_Names:
Abapresin
Apo-Guanethidine
Eutensol
Ismelin
Oktadin

# CAS_Registry_Number:
645-43-2

# ChEBI_ID:
5557

# Chemical_Formula:
C10H22N4

# Chemical_IUPAC_Name:
2-[2-(azocan-1-yl)ethyl]guanidine

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. [PubChem]

# Dosage_Forms:
Tablet	Oral

# Drug_Category:
Adrenergic Agents
Antihypertensive Agents
Sympatholytics

# Drug_Interactions:
Acetophenazine	Acetophenazine may decrease the effect of guanethidine.
Amitriptyline	The tricyclic antidepressant, amitriptyline, decreases the effect of guanethidine.
Amoxapine	The tricyclic antidepressant, amoxapine, decreases the effect of guanethidine.
Amphetamine	Amphetamine may decrease the effect of guanethidine.
Benzphetamine	Benzphetamine may decrease the effect of guanethidine.
Chlorpromazine	Chlorpromazine may decrease the effect of guanethidine.
Chlorprothixene	Chlorprothixene may decrease the effect of guanethidine.
Clomipramine	The tricyclic antidepressant, clomipramine, decreases the effect of guanethidine.
Desipramine	The tricyclic antidepressant, desipramine, decreases the effect of guanethidine.
Dexfenfluramine	Dexfenfluramine may decrease the effect of guanethidine.
Dextroamphetamine	Dextroamphetamine may decrease the effect of guanethidine.
Diethylpropion	Diethylpropion may decrease the effect of guanethidine.
Dobutamine	Dobutamine may decrease the effect of guanethidine.
Dopamine	Dopamine may decrease the effect of guanethidine.
Doxepin	The tricyclic antidepressant, doxepin, decreases the effect of guanethidine.
Ephedra	Ephedra may decrease the effect of guanethidine.
Ephedrine	Ephedrine may decrease the effect of guanethidine.
Epinephrine	Epinephrine may decrease the effect of guanethidine.
Ethopropazine	Ethopropazine may decrease the effect of guanethidine.
Fenfluramine	Fenfluramine may decrease the effect of guanethidine.
Fluphenazine	Fluphenazine may decrease the effect of guanethidine.
Haloperidol	Haloperidol may decrease the effect of guanethidine.
Imipramine	The tricyclic antidepressant, imipramine, may increase the sympathomimetic effect of guanethidine.
Isocarboxazid	Isocarboxazid may decrease the effect of guanethidine.
Mazindol	Mazindol may decrease the effect of guanethidine.
Mesoridazine	Mesoridazine may decrease the effect of guanethidine.
Metaraminol	Metaraminol may decrease the effect of guanethidine.
Methamphetamine	Methamphetamine may decrease the effect of guanethidine.
Methdilazine	Methdilazine may decrease the effect of guanethidine.
Methotrimeprazine	Methotrimeprazine may decrease the effect of guanethidine.
Methoxamine	Methoxamine may decrease the effect of guanethidine.
Methylphenidate	Methylphenidate may decrease the effect of guanethidine.
Norepinephrine	Norepinephrine may decrease the effect of guanethidine.
Nortriptyline	The tricyclic antidepressant, nortriptyline, decreases the effect of guanethidine.
Pargyline	Pargyline may decrease the effect of guanethidine.
Perphenazine	Perphenazine may decrease the effect of guanethidine.
Phendimetrazine	Phendimetrazine may decrease the effect of guanethidine.
Phenelzine	Phenelzine may decrease the effect of guanethidine.
Phenmetrazine	Phenmetrazine may decrease the effect of guanethidine.
Phentermine	Phentermine may decrease the effect of guanethidine.
Phenylephrine	Phenylephrine may decrease the effect of guanethidine.
Phenylpropanolamine	Phenylpropanolamine may decrease the effect of guanethidine.
Prochlorperazine	Prochlorperazine may decrease the effect of guanethidine.
Promazine	Promazine may decrease the effect of guanethidine.
Promethazine	Promethazine may decrease the effect of guanethidine.
Propericiazine	Propericiazine may decrease the effect of guanethidine.
Propiomazine	Propiomazine may decrease the effect of guanethidine.
Protriptyline	The tricyclic antidepressant, protriptyline, decreases the effect of guanethidine.
Pseudoephedrine	Pseudoephedrine may decrease the effect of guanethidine.
Thiethylperazine	Thiethylperazine may decrease the effect of guanethidine.
Thioridazine	Thioridazine may decrease the effect of guanethidine.
Thiothixene	Thiothixene may decrease the effect of guanethidine.
Tranylcypromine	Tranylcypromine may decrease the effect of guanethidine.
Trifluoperazine	Trifluoperazine may decrease the effect of guanethidine.
Triflupromazine	Triflupromazine may decrease the effect of guanethidine.
Trimeprazine	Trimeprazine may decrease the effect of guanethidine.
Trimipramine	The tricyclic antidepressant, trimipramine, decreases the effect of guanethidine.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
0.8

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Very soluble

# Food_Interactions:
Take without regard to meals.

# GenBank_ID:
Not Available

# Generic_Name:
Guanethidine

# HET_ID:
Not Available

# Half_Life:
1.5 days

# InChI_Identifier:
InChI=1S/C10H22N4/c11-10(12)13-6-9-14-7-4-2-1-3-5-8-14/h1-9H2,(H4,11,12,13)

# InChI_Key:
InChIKey=ACGDKVXYNVEAGU-UHFFFAOYSA-N

# Indication:
For the treatment of moderate and severe hypertension, either alone or as an adjunct, and for the treatment of renal hypertension.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D02237

# LIMS_Drug_ID:
1170

# Mechanism_Of_Action:
Guanethidine acts at the sympathetic neuroeffector junction by inhibiting or interfering with the release and/or distribution of norepinephrine, rather than acting at the effector cell by inhibiting the association of norepinephrine with its receptors. It is taken up by norepinephrine transporters. It becomes concentrated in NE transmitter vesicles, replacing NE in these vesicles. This leads to a gradual depletion of NE stores in the nerve endings. Once inside the terminal it blocks the release of noradrenaline in response to arrival of an action potential. In contrast to ganglionic blocking agents, Guanethidine suppresses equally the responses mediated by alpha-and beta-adrenergic receptors but does not produce parasympathetic blockade. Since sympathetic blockade results in modest decreases in peripheral resistance and cardiac output, Guanethidine lowers blood pressure in the supine position. It further reduces blood pressure by decreasing the degree of vasoconstriction that normally results from reflex sympathetic nervous activity upon assumption of the upright posture, thus reducing venous return and cardiac output more.

# Melting_Point:
250 Â°C (sulfate salt)

# Molecular_Weight_Avg:
198.3085

# Molecular_Weight_Mono:
198.184446724

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA449823

# Pharmacology:
High blood pressure can cause the heart and arteries to not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. High blood pressure may also increase the risk of heart attacks. These problems may be less likely to occur if blood pressure is controlled. Guanethidine works by decreasing the heart rate and relaxing the blood vessels so that blood can flow more easily through the body, thereby reducing these risks. It is a postganglionic sympathetic nerve terminal blocker that prevents the release of norepinephrine from nerve terminals.

# Predicted_LogP_Hydrophobicity:
0.89

# Predicted_LogS:
-1.9

# Predicted_Water_Solubility:
2.25e+00 g/l

# Primary_Accession_No:
DB01170

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
3518

# PubChem_Substance_ID:
46507567

# RxList_Link:
http://www.rxlist.com/cgi/generic3/guanethidine.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD01007

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC(N)=NCCN1CCCCCCC1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Guanethidine Monosulfate
Guanethidine Sulphae

# Synthesis_Reference:
Not Available

# Toxicity:
Side effects include drowsiness, dizziness, tiredness or confusion. LD<sub>50</sub>=1000 mg/kg (mouse, oral)

# Update_Date:
2013-02-08 16:19:58 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Guanethidine

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_1_ID:
4512

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P08684

# Drug_Target_1_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11403930	Joyce PI, Atcheson R, Marcus RJ, Heffernan AM, Rowbotham DJ, Lambert DG: Interaction of local anaesthetic agents with the endogenous norepinephrine transporter in SH-SY5Y human neuroblastoma cells. Neurosci Lett. 2001 Jun 15;305(3):161-4.
16126010	Yi E, Love JA: Alpha-adrenergic modulation of synaptic transmission in rabbit pancreatic ganglia. Auton Neurosci. 2005 Oct 30;122(1-2):45-57. Epub 2005 Aug 25.
8710929	Galli A, Blakely RD, DeFelice LJ: Norepinephrine transporters have channel modes of conduction. Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8671-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
SLC6A2

# Drug_Target_1_GenBank_ID_Gene:
M65105

# Drug_Target_1_GenBank_ID_Protein:
189258

# Drug_Target_1_GeneCard_ID:
SLC6A2

# Drug_Target_1_Gene_Name:
SLC6A2

# Drug_Target_1_Gene_Sequence:
>1854 bp
ATGCTTCTGGCGCGGATGAACCCGCAGGTGCAGCCCGAGAACAACGGGGCGGACACGGGT
CCAGAGCAGCCCCTTCGGGCGCGCAAAACTGCGGAGCTGCTGGTGGTGAAGGAGCGCAAC
GGCGTCCAGTGCCTGCTGGCGCCCCGCGACGGCGACGCGCAGCCCCGGGAGACCTGGGGC
AAGAAGATCGACTTCCTGCTGTCCGTAGTCGGCTTCGCAGTGGACCTGGCCAACGTGTGG
CGCTTCCCCTACCTCTGCTACAAGAACGGCGGCGGTGCCTTCTTGATCCCGTACACACTG
TTCCTTATCATCGCGGGGATGCCCCTGTTCTACATGGAGCTGGCTCTGGGACAGTACAAC
CGGGAGGGGGCTGCCACCGTTTGGAAAATCTGCCCATTCTTCAAAGGCGTTGGCTATGCT
GTCATCCTGATCGCCCTGTACGTTGGCTTCTACTACAACGTCATCATCGCCTGGTCACTC
TACTACCTCTTCTCCTCCTTCACCCTCAACCTGCCCTGGACCGACTGTGGCCACACCTGG
AACAGCCCCAACTGTACCGACCCCAAGCTCCTCAATGGCTCCGTGCTTGGCAACCACACC
AAGTACTCCAAGTACAAGTTCACGCCGGCAGCCGAGTTTTATGAGCGTGGTGTCCTGCAC
CTTCACGAGAGCAGCGGGATTCATGACATCGGCCTGCCCCAGTGGCAGCTCTTGCTCTGT
CTGATGGTCGTCGTCATCGTCTTGTATTTTAGCCTCTGGAAAGGGGTGAAGACATCAGGA
AAGGTGGTGTGGATCACAGCCACGCTGCCTTACTTCGTGCTGTTCGTGCTCCTGGTCCAT
GGCGTCACGCTGCCCGGAGCCTCCAATGGCATCAATGCCTACCTGCACATCGACTTCTAC
CGCTTGAAAGAGGCCACGGTATGGATTGATGCCGCAACTCAGATATTTTTTTCCTTGGGG
GCTGGATTTGGAGTATTGATTGCATTTGCCAGTTACAACAAATTTGACAACAACTGTTAC
AGGGATGCCCTGCTGACCAGCAGCATCAACTGTATCACCAGCTTCGTCTCTGGGTTCGCC
ATCTTCTCCATCCTTGGTTACATGGCCCATGAACACAAGGTCAACATTGAGGATGTGGCC
ACAGAAGGAGCTGGCCTAGTGTTCATCCTGTATCCAGAGGCCATTTCTACCCTGTCTGGA
TCTACATTCTGGGCTGTTGTGTTTTTCGTCATGCTCCTGGCGCTGGGCCTTGACAGCTCA
ATGGGAGGCATGGAGGCTGTCATCACGGGCCTGGCAGATGACTTCCAGGTCCTGAAGCGA
CACCGGAAACTCTTCACATTTGGCGTCACCTTCAGCACTTTCCTTCTCGCCCTGTTCTGC
ATAACCAAGGGTGGAATTTACGTCTTGACCCTCCTGGACACCTTTGCTGCGGGCACCTCC
ATCCTTTTTGCTGTCCTCATGGAAGCCATCGGAGTTTCCTGGTTTTATGGAGTGGACAGG
TTCAGCAACGACATCCAGCAGATGATGGGGTTCAGGCCGGGTCTATACTGGAGACTGTGC
TGGAAGTTCGTCAGTCCTGCCTTCCTCCTGTTCGTGGTTGTGGTCAGCATCATCAACTTC
AAGCCACTCACCTACGACGACTACATCTTCCCGCCCTGGGCCAACTGGGTGGGGTGGGGC
ATCGCCCTGTCCTCCATGGTCCTGGTGCCCATCTACGTCATCTATAAGTTCCTCAGCACG
CAGGGCTCTCTTTGGGAGAGACTGGCCTATGGCATCACGCCAGAGAACGAGCACCACCTG
GTGGCTCAGAGGGACATCAGACAGTTCCAGTTGCAACACTGGCTGGCCATCTGA

# Drug_Target_1_General_Function:
Involved in neurotransmitter:sodium symporter activity

# Drug_Target_1_General_References:
10684912	Shannon JR, Flattem NL, Jordan J, Jacob G, Black BK, Biaggioni I, Blakely RD, Robertson D: Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med. 2000 Feb 24;342(8):541-9.
11343649	Torres GE, Yao WD, Mohn AR, Quan H, Kim KM, Levey AI, Staudinger J, Caron MG: Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1. Neuron. 2001 Apr;30(1):121-34.
2008212	Pacholczyk T, Blakely RD, Amara SG: Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature. 1991 Mar 28;350(6316):350-4.
7488042	Porzgen P, Bonisch H, Bruss M: Molecular cloning and organization of the coding region of the human norepinephrine transporter gene. Biochem Biophys Res Commun. 1995 Oct 24;215(3):1145-50.

# Drug_Target_1_HGNC_ID:
HGNC:11048

# Drug_Target_1_HPRD_ID:
01232

# Drug_Target_1_ID:
540

# Drug_Target_1_Locus:
16q12.2

# Drug_Target_1_Molecular_Weight:
69333

# Drug_Target_1_Name:
Sodium-dependent noradrenaline transporter

# Drug_Target_1_Number_of_Residues:
617

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Desipramine Pathway	SMP00423
Disulfiram Pathway	SMP00429
Imipramine Pathway	SMP00422

# Drug_Target_1_Pfam_Domain_Function:
PF00209	SNF

# Drug_Target_1_Protein_Sequence:
>Sodium-dependent noradrenaline transporter
MLLARMNPQVQPENNGADTGPEQPLRARKTAELLVVKERNGVQCLLAPRDGDAQPRETWG
KKIDFLLSVVGFAVDLANVWRFPYLCYKNGGGAFLIPYTLFLIIAGMPLFYMELALGQYN
REGAATVWKICPFFKGVGYAVILIALYVGFYYNVIIAWSLYYLFSSFTLNLPWTDCGHTW
NSPNCTDPKLLNGSVLGNHTKYSKYKFTPAAEFYERGVLHLHESSGIHDIGLPQWQLLLC
LMVVVIVLYFSLWKGVKTSGKVVWITATLPYFVLFVLLVHGVTLPGASNGINAYLHIDFY
RLKEATVWIDAATQIFFSLGAGFGVLIAFASYNKFDNNCYRDALLTSSINCITSFVSGFA
IFSILGYMAHEHKVNIEDVATEGAGLVFILYPEAISTLSGSTFWAVVFFVMLLALGLDSS
MGGMEAVITGLADDFQVLKRHRKLFTFGVTFSTFLLALFCITKGGIYVLTLLDTFAAGTS
ILFAVLMEAIGVSWFYGVDRFSNDIQQMMGFRPGLYWRLCWKFVSPAFLLFVVVVSIINF
KPLTYDDYIFPPWANWVGWGIALSSMVLVPIYVIYKFLSTQGSLWERLAYGITPENEHHL
VAQRDIRQFQLQHWLAI

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals

# Drug_Target_1_SwissProt_ID:
P23975

# Drug_Target_1_SwissProt_Name:
SC6A2_HUMAN

# Drug_Target_1_Synonyms:
NET
Norepinephrine transporter

# Drug_Target_1_Theoretical_pI:
7.53

# Drug_Target_1_Transmembrane_Regions:
65-85
93-112
136-156
235-253
262-279
315-332
344-365
398-417
444-462
478-498
519-538
557-575

#END_DRUGCARD DB01170
